Phathom Pharmaceuticals Net Worth
Phathom Pharmaceuticals Net Worth Breakdown | PHAT |
Phathom Pharmaceuticals Net Worth Analysis
Phathom Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Phathom Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Phathom Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Phathom Pharmaceuticals' net worth analysis. One common approach is to calculate Phathom Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Phathom Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Phathom Pharmaceuticals' net worth. This approach calculates the present value of Phathom Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Phathom Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Phathom Pharmaceuticals' net worth. This involves comparing Phathom Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Phathom Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Phathom Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Phathom Pharmaceuticals' net worth research are outlined below:
| Phathom Pharmaceuticals generated a negative expected return over the last 90 days | |
| Phathom Pharmaceuticals has high historical volatility and very poor performance | |
| Phathom Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 682 K. Net Loss for the year was (201.59 M) with profit before overhead, payroll, taxes, and interest of 21.95 M. | |
| Phathom Pharmaceuticals currently holds about 207.39 M in cash with (137.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.39. | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Further weakness as Phathom Pharmaceuticals drops 12 percent this week, taking five-year losses to 81 percent - Simply Wall St |
Phathom Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Phathom Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Phathom Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Phathom Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Phathom Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Phathom Pharmaceuticals backward and forwards among themselves. Phathom Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Phathom Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Gilder Gagnon Howe & Co Llc | 2024-09-30 | 1.6 M | Checkpoint Capital Lp | 2024-09-30 | 1.5 M | Orbimed Advisors, Llc | 2024-09-30 | 1.4 M | Federated Hermes Inc | 2024-09-30 | 1.4 M | Fmr Inc | 2024-09-30 | 1.3 M | Decheng Capital Llc | 2024-09-30 | 1.2 M | Gw&k Investment Management, Llc | 2024-09-30 | 1.1 M | Catalys Pacific Llc | 2024-09-30 | 1.1 M | 683 Capital Management Llc | 2024-09-30 | 1 M | Medicxi Ventures Management (jersey) Ltd | 2024-09-30 | 7.5 M | Jennison Associates Llc | 2024-09-30 | 5.9 M |
Follow Phathom Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 409.58 M.Market Cap |
|
Project Phathom Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.51) | (0.54) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | 2.49 | 2.62 |
When accessing Phathom Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Phathom Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Phathom Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Phathom Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Phathom Pharmaceuticals. Check Phathom Pharmaceuticals' Beneish M Score to see the likelihood of Phathom Pharmaceuticals' management manipulating its earnings.
Evaluate Phathom Pharmaceuticals' management efficiency
Phathom Pharmaceuticals has return on total asset (ROA) of (0.5767) % which means that it has lost $0.5767 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (34.89) %, meaning that it created substantial loss on money invested by shareholders. Phathom Pharmaceuticals' management efficiency ratios could be used to measure how well Phathom Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 2.62 in 2025, whereas Return On Tangible Assets are likely to drop (0.46) in 2025. At this time, Phathom Pharmaceuticals' Non Current Liabilities Total is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 373.7 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 26.7 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.63) | (1.55) | |
| Tangible Book Value Per Share | (1.63) | (1.55) | |
| Enterprise Value Over EBITDA | (1.28) | (1.34) | |
| Price Book Value Ratio | (5.79) | (6.08) | |
| Enterprise Value Multiple | (1.28) | (1.34) | |
| Price Fair Value | (5.79) | (6.08) | |
| Enterprise Value | 259.8 M | 246.8 M |
Evaluating the management effectiveness of Phathom Pharmaceuticals allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Phathom Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Phathom Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Phathom Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Phathom Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Phathom Pharmaceuticals Corporate Filings
F4 | 23rd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 11th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 5th of November 2024 Other Reports | ViewVerify |
Phathom Pharmaceuticals Earnings per Share Projection vs Actual
Phathom Pharmaceuticals Corporate Management
| Anthony Guzzo | Chief Officer | Profile | |
| Joseph JD | Chief Officer | Profile | |
| Tom Harris | Chief Officer | Profile | |
| Martin Gilligan | Chief Officer | Profile | |
| JD Esq | General Secretary | Profile | |
| David Socks | CoFounder Director | Profile |
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.